Abstract:Chimeric antigen receptor T cell (CAR-T) therapy is a late-model of immune cell therapy that has been shown to be effective in refractory/recurrent B-cell leukemia and lymphoma. Compared with the traditional anti-tumor methods, CAR-T cell therapy has the advantages of higher specificity, stronger lethality and longer-lasting efficacy. Although CAR-T cells have made significant progress in the treatment of hematologic malignancies, diverse difficulties remain in the treatment of solid tumors, including immune escape due to tumor antigen heterogeneity, preventing entry or limiting the persistence of CAR-T cells by physical or cytokine barriers and along with other immunosuppressive molecule and cells in the tumor microenvironment (TME). Otherwise, the intracellular signaling of CAR also impact on CAR-T cells persistence. Appropriate modification of intracellular costimulatory molecular signal in the structure of CAR or coexpression of CAR and cytokines can provide a way to enhance CAR-T cells activity. Additionally, CAR-T cells dysfunction due to T cell exhaustion is associated with multi-factors, especially transcription factors, such as c-Jun, NR4A. Engineering CAR-T cells to coexpress or knockout transcription factors in favor of T<sub>CM</sub> memory CAR-T cells differentiation was proved to prolonged the survival of CAR-T cells. Finally, combination of CAR-T cells with oncolytic viruses, nanoparticles or immune checkpoint inhibitors provides an effective measure to improve CAR-T cells function. Here, we discuss all of these advances and challenges and review promising strategies for treating solid tumors. In particular, we also highlight that CAR-T cells have enormous potential to be used in combination with other immunotherapies.

CAR-T Cells for Cancer Immunotherapy—the Barriers Ahead and the Paths Through

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

Influencing factors and solution strategies of chimeric antigen receptor T-cell therapy (CAR-T) cell immunotherapy

The progress of CAR-T therapy in cancer and beyond

A long way to the battlefront: CAR T cell therapy against solid cancers.

Charting new paradigms for CAR-T cell therapy beyond current Achilles heels

Recent advances in CAR-T cell engineering

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review)

Challenges and innovations in CAR-T cell therapy: a comprehensive analysis

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

CAR-T in solid tumors: Blazing a new trail through the brambles

Current progress in CAR-T cell therapy for tumor treatment

Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer

Challenges and optimal strategies of CAR T therapy for hematological malignancies.

Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy

CAR-T cell therapy: current limitations and potential strategies

CAR‐T cell therapy: A breakthrough in traditional cancer treatment strategies (Review)

Toxicities and related improvements of CAR-T Cell in the treatment of cancer